In continuation to intimation dated October 17, 2025, regarding the Board Meeting Notice, Gland Pharma has informed that the Board of Directors of the Company at its Meeting held today, Monday, November 03, 2025, has considered and approved the Unaudited Financial Results (standalone and consolidated) along with the Limited Review Report(s) for the quarter and half year ended September 30, 2025, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations’) which has been duly reviewed and recommended by the Audit Committee. In this regard, the company has enclosed copies of the: 1. Unaudited Financial Results (standalone and consolidated) along with Limited Review Report(s) of the Company for the quarter and half year ended September 30, 2025, prepared in compliance with Indian Accounting Standards (Ind AS). 2. Press Release and Investor Presentation on the financial results of the Company for the above period. The Board Meeting commenced at 15.00 Hrs. IST and ended at 16.10 Hrs. IST.
The above information is a part of company’s filings submitted to BSE.
